Company intelligence / Profile preview
UTC Therapeutics
Singapore, Singaporeutctherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
UTC Therapeutics is developing next-generation T-cell therapies to overcome tumor microenvironment challenges. Their UCLM-802 program for thymic carcinoma uses T-cells genetically engineered to express chimeric antigen receptors targeting mesothelin antigen. The company recently had a patent granted on May 28, 2024, for BCMA targeting antibodies and chimeric antigen receptors.[1][2]
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapymRNAantibodies
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Novartis (collaboration mentioned)
Beyond the preview
Go deeper on UTC Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTC Therapeutics.